What’s Next? Five Things To Look Out For In March
Key Alvotech Inspection Looms, CJEU To Weigh Tecfidera Exclusivity
Executive Summary
Prepare for all the biggest industry actions and events in March 2023 with Generics Bulletin’s monthly column.
You may also be interested in...
Teva Will Stick To Hybrid Biosimilar Model, With Cash In Its Thinking
Teva’s senior management spoke at length about the company’s ambitions in the biosimilar space, ahead of the planned US launch of partner Alvotech’s AVT02 proposed interchangeable high-concentration (Humira) adalimumab biosimilar on 1 July.
Who’s Hired? Nichi-Iko Looks To Sandoz For Fresh Leadership
Nichi-Iko has revealed its choice of new leadership, looking to Sandoz Japan for its next president and CEO. Meanwhile, Ethypharm and Krka have made fresh appointments in the UK and Centrient has named a new chief quality officer.
Alvotech Lines Up FDA Inspection Ahead Of Adalimumab Action
Alvotech has secured a US FDA reinspection of its Reykjavik plant in March, ahead of the agency’s April goal date for action on the firm’s pending application for a high-concentration, interchangeable adalimumab biosimilar rival to Humira.